BioSyent Inc.
2601 Matheson Boulevard E.
Suite 5
Mississauga
Ontario
L4W 5A8
Canada
Tel: 905-206-0013
Fax: 905-206-1413
106 articles about BioSyent Inc.
-
BioSyent Schedules Q3 and YTD 2021 Earnings Release for November 18, 2021
11/10/2021
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2021 on Thursday, November 18, 2021 at 5:00pm ET. A presentation on the Company’s third quarter and year-to-date 2021 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.
-
BioSyent Announces Launch of New FeraMAX® Pd Powder 15
10/19/2021
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX ® Pd Powder 15 by its subsidiary, BioSyent Pharma Inc., in Canada.
-
BioSyent Releases Q2 and H1 2021 Financial Results
8/25/2021
BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2021.
-
BioSyent Schedules Q2 and H1 2021 Earnings Release for August 25, 2021
8/17/2021
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2021 on Wednesday, August 25, 2021 at 8:00am ET.
-
BioSyent Signs Exclusive Technology Agreement
7/13/2021
BioSyent Inc. is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an agreement to license a unique technology application to support better treatment outcomes for patients with iron deficiencies in Canada and BioSyent’s international markets.
-
BioSyent Releases Financial Results for Q1 2021
5/27/2021
BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2021. Key highlights include: Record first quarter (Q1) 2021 Net Revenues of $7,419,889 increased by 22% versus Q1 2020 Q1 2021 Canadian Pharmaceutical Net Revenues of $6,233,763 increased by 5% versus Q1 2020 Q1 2021 International Pharmaceutical Net Revenues of $1,140,279 increased by 1,578% versus Q1 2020 Q1 2021
-
BioSyent Schedules Q1 2021 Earnings Release for May 27, 2021
5/20/2021
BioSyent Inc. will be reporting its financial results for the three months ended March 31, 2021 on Thursday, May 27, 2021 at 8:00am EDT.
-
BioSyent to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference
4/14/2021
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference
-
BioSyent Announces Grant of Restricted Share Units
3/19/2021
BioSyent Inc. announces that its Board of Directors has approved a grant of 67,252 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan.
-
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2020
3/17/2021
BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2020.
-
BioSyent Schedules Q4 and Full Year 2020 Earnings Release for March 17, 2021
3/11/2021
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2020 on Wednesday, March 17, 2021.
-
BioSyent Launches Combogesic®, First-Ever Acetaminophen + Ibuprofen Combination Tablet in Canada Now AvailableCanadians have a new pain relief option
12/16/2020
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of Combogesic ® to Canadian wholesalers. Combogesic ® is the first fixed-dose combination of acetaminophen and ibuprofen in a single tablet in Canada and is indicated for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Combining two
-
BioSyent Announced Renewal of Normal Course Issuer Bid
12/11/2020
MISSISSAUGA, Ontario, Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 950,000 of its common shares (“Shares”) over a 12-month period, representing approximately 7.42% of the Shares outstanding as of December 11, 2020. The NCIB will commence
-
BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020
11/26/2020
BioSyent Inc. released its financial results for the three and nine months ended September 30, 2020.
-
BioSyent Schedules Q3 and YTD 2020 Earnings Release for November 26, 2020
11/17/2020
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2020 on Thursday, November 26, 2020. A presentation on the Company’s third quarter and year-to-date 2020 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange und
-
Biosyent Announces Launch of New FeraMAX® Pd Therapeutic 150
11/5/2020
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX® Pd Therapeutic 150, the first new product incorporating FeraMAX® Pd, a new oral iron supplement delivery system, by its subsidiary BioSyent Pharma Inc. in Canada.
-
BioSyent Named to the Growth List Ranking of Canada’s Fastest-Growing Companies for Eighth Consecutive Year
10/15/2020
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been included in the 32nd annual Growth List, the definitive ranking of Canada’s Fastest-Growing Companies by Canadian Business and Maclean’s.
-
BioSyent Announces Introduction of New FeraMAX® Pd
10/5/2020
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the introduction of FeraMAX ® Pd, a new oral iron supplement formulation, by its subsidiary BioSyent Pharma Inc. FeraMAX ® Pd is a patented delivery system for the treatment of iron deficiency anemia and will be the foundation of future product developments. BioSyent Pharma has a deep expertise and experience in the iron deficiency anemia therapy and pre
-
BioSyent Signs Exclusive Agreement for New Women’s Health Product
10/1/2020
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive License and Supply Agreement with a European partner for a new product in the women’s health market for Canada. The product has been approved for sale in Canada, the U.S.A., Europe and in several other markets around the world. BioSyent intends to launch the product to the Canadian market in Q2 2021. “We
-
BioSyent Releases Q2 and H1 2020 Results
8/26/2020
BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30, 2020. Key highlights include: Second quarter (Q2) 2020 Net Revenues of $4,771,255 decreased by 7% versus Q2 2019 First half (H1) 2020 Net Revenues of $10,834,101 increased by 12% versus H1 2019 Q2 2020 Canadian Pharmaceutical Net Revenues of $4,415,900 decreased by 9% versus Q2 2019 H1 2020 Canadi